HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ro 11-1430, a new retinoic acid derivative for the topical treatment of acne.

Abstract
The clinical efficacy and tolerance of a new retinoic acid derivative, Ro 11-1430, in the treatment of acne vulgaris have been compared with those of tretinoin in a double-blind trial with 60 patients during 8 weeks. The efficacy of both drugs was good. Tretinoin showed a tendency to give better effect but this was not statistically significant. However, tolerance of the new derivative was better. 48 of the patients were treated with Ro 11-1430 for another 3 months with good effect and tolerance. In a long-term study, 32 patients with previous irritation of tretinoin have been treated with Ro 11-1430 between 1.5 and 17 months with good tolerance.
AuthorsK Nordin, T Fredriksson, C Rylander
JournalDermatologica (Dermatologica) Vol. 162 Issue 2 Pg. 104-11 ( 1981) ISSN: 0011-9075 [Print] Switzerland
PMID6454596 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
Chemical References
  • Tretinoin
  • motretinide
Topics
  • Acne Vulgaris (drug therapy)
  • Administration, Topical
  • Adolescent
  • Adult
  • Chemical Phenomena
  • Chemistry
  • Child
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Tretinoin (administration & dosage, analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: